Thomas Clozel is the co-founder and CEO of Owkin, an AI biotech company revolutionizing the healthcare industry. With a background in clinical research, Clozel has been instrumental in leading Owkin since its inception in 2016. Under his leadership, the company has achieved significant milestones, including raising substantial funding and forming strategic partnerships with major pharmaceutical companies.
Who is the CEO of Owkin?
Thomas Clozel, a clinical research doctor and the son of biotech pioneers Jean-Paul and Martine Clozel, co-founded Owkin in 2016. As the CEO, he has steered the company to become a leader in AI-driven healthcare solutions. Clozel's vision for Owkin involves leveraging artificial intelligence to revolutionize drug discovery, optimize clinical trials, and develop advanced diagnostics.
His leadership has been pivotal in raising substantial funding and forming strategic partnerships with major pharmaceutical companies, positioning Owkin at the forefront of biotech innovation.
Work History
Thomas Clozel's work history includes notable positions at prestigious institutions. Here are some of the places he has worked previously:
- Joan & Sanford I. Weill Medical College of Cornell University - Research Fellowship in Hematology-oncology (2009 to 2011)
- Icahn School of Medicine at Mount Sinai - Clinical Rotation in Neurology Department (2006)
Education History
Thomas Clozel's educational journey is marked by a series of prestigious institutions and specialized training. He completed his Master 2 parcours recherche in Biochimie, Cellules, Cibles Thérapeutiques (BC2T) from 2009 to 2010, which provided him with a strong foundation in biochemical research and therapeutic targets. Prior to that, he undertook a rotation residency at Mount Sinai Medical Center from July 2004 to January 2005, gaining valuable clinical experience. His extensive training continued with an internat at Hôpital Necker-Enfants Malades from January 2006 to January 2012, where he honed his skills in pediatric care. This diverse and rigorous educational background has equipped Clozel with the expertise necessary to lead innovative projects in the biotech and healthcare sectors.
When did Thomas Clozel join Owkin?
Thomas Clozel co-founded Owkin in 2016, marking the beginning of his journey with the AI biotech company. As one of the founders, he has been with Owkin since its inception and has played a crucial role in its development and success. This means Clozel has been with the company for approximately eight years as of 2024. His leadership and vision have been instrumental in steering Owkin towards becoming a leader in AI-driven healthcare solutions.